Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16519851 | 1.00 | ADORA2A (0.38) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL881455 | 0.89 | ADORA2A (0.37) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL14996141 | 0.89 | ADORA2A (0.37) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL12393219 | 0.89 | ADORA2A (0.38) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL12243128 | 0.89 | ADORA2A (0.38) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL14038976 | 0.87 | TMPRSS2 (0.36) | ADORA2ATMPRSS2 | |
| SCHEMBL12393410 | 0.87 | TMPRSS2 (0.36) | ADORA2ATMPRSS2 | |
| SCHEMBL12393365 | 0.87 | ADORA2A (0.37) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL16519887 | 0.85 | ADORA2A (0.36) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL12243243 | 0.85 | ADORA2A (0.36) | ADORA2ATMPRSS2PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2937350-A1 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2268642-B1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8853171-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853171-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, TYMS | ADORA2A 109/4885TMPRSS2 4701/4885PI4KA 420/4885 |
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | ADORA2A 93/4885TMPRSS2 1945/4885PI4KA 110/4885 |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | ADORA2A 130/4885TMPRSS2 4714/4885PI4KA 402/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | ADORA2A 93/4885TMPRSS2 1945/4885PI4KA 110/4885 |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | ADORA2A 130/4885TMPRSS2 4714/4885PI4KA 402/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | ADORA2A 162/4885TMPRSS2 4673/4885PI4KA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.